Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,620
  • Shares Outstanding, K 25,808
  • Annual Sales, $ 28,800 K
  • Annual Income, $ 9,390 K
  • 60-Month Beta 1.53
  • Price/Sales 4.24
  • Price/Cash Flow 8.14
  • Price/Book 2.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.50
  • Prior Year 1.00
  • Growth Rate Est. (year over year) -136.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.13 +15.98%
on 07/31/20
4.85 -1.24%
on 08/13/20
+0.55 (+12.97%)
since 07/14/20
3-Month
4.07 +17.69%
on 07/13/20
10.71 -55.28%
on 05/26/20
-3.61 (-42.98%)
since 05/14/20
52-Week
2.23 +114.79%
on 03/19/20
11.20 -57.23%
on 09/17/19
-1.83 (-27.60%)
since 08/14/19

Most Recent Stories

More News
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates

AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

AVEO : 4.79 (+1.27%)
EBS : 133.42 (-1.13%)
HZNP : 72.82 (+0.57%)
ALIM : 6.09 (-5.14%)
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AVEO : 4.79 (+1.27%)
AVEO: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Monday reported a loss of $7.3 million in its second quarter.

AVEO : 4.79 (+1.27%)
AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update

--- Preparations Underway to Support Potential Commercial Launch of Tivozanib in the U.S.; New Debt and Equity Financings, Partnership Milestones Potentially Provide for Working Capital into 2022 -

AVEO : 4.79 (+1.27%)
AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility

AVEO Oncology (Nasdaq: AVEO) today announced the closing of a tranched, $35 million debt facility with Hercules Capital, Inc. (NYSE: HTGC) and its affiliates. The new facility has a maturity of 36 months,...

AVEO : 4.79 (+1.27%)
HTGC : 11.65 (-0.77%)
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q2 Earnings Expected to Decline

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO : 4.79 (+1.27%)
AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin

AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the...

AVEO : 4.79 (+1.27%)
AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares

AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters...

AVEO : 4.79 (+1.27%)
AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock

AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share....

AVEO : 4.79 (+1.27%)
AVEO Announces Proposed Public Offering of Common Stock

AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant...

AVEO : 4.79 (+1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AVEO with:

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

2nd Resistance Point 4.93
1st Resistance Point 4.86
Last Price 4.79
1st Support Level 4.67
2nd Support Level 4.55

See More

52-Week High 11.20
Fibonacci 61.8% 7.77
Fibonacci 50% 6.72
Fibonacci 38.2% 5.66
Last Price 4.79
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar